In the gene therapy market, vectors serve as gene delivery devices to introduce transgenes into cells for replication and expression. These DNA molecules contain transgene inserts and additional sequences that act as pillars. Vectors play a vital role in conveying genetic information to target cells, enabling the isolation, multiplication, and expression of the transgene. Understanding the functions and types of vectors is crucial for advancing gene therapy and addressing various medical challenges.
According to Data Bridge Market Research, the Viral Vector and Vaccine Market accounted USD 513.43 million in 2022, is expected to reach USD 2,016.62 million by 2030, at a CAGR of 18.65% during the forecast period 2023 to 2030.
“Growing frequency of cancer and genetic complaints”
According to the World Health Organization, lung cancer is the leading cause of cancer-related deaths, followed by breast cancer and colorectal cancer. The rising prevalence of cancer, genetic diseases, and infectious diseases is a significant driver for the global viral vector and vaccine market. This increasing demand stems from the need for vector-based gene therapies, cell therapies, and vaccines to address these health conditions, thus propelling the growth of the market.
What restraints the growth of viral vector and vaccine market?
“Complex manufacturing process”
The complex manufacturing process of viral vector vaccines in the viral vector and vaccine market poses disadvantages. The production involves modifying viruses to deliver genetic material, requiring sophisticated techniques for production, purification, and quality control. This complexity can lead to higher costs, longer development timelines, and manufacturing challenges, limiting scalability and availability of viral vector vaccines, impacting market growth.
Segmentation: Global Viral Vector and Vaccine Market
The viral vector and vaccine market is segmented on the basis of type, workflow, application, disease and end-user.
- On the basis of type, the viral vector and vaccine market is segmented into adenovirus, retrovirus, plasmid DNA, AAV, lentivirus, others.
- On the basis of workflow, the viral vector and vaccine market is segmented into upstream processing, downstream processing
- On the basis of application the viral vector and vaccine market is segmented into antisense and RNAI, gene therapy, cell therapy, vaccinology
- On the basis of disease the viral vector and vaccine market is segmented into cancer, genetic disorders, infectious diseases, others
- On the basis of end-user the viral vector and vaccine market is segmented into pharmaceutical and biopharmaceutical companies, research institutes.
Regional Insights: North America is expected to dominate the viral vector and vaccine market
Rising number of infectious disease patients, North America is expected to dominate the market share. This could be attributed to factors such as advanced healthcare infrastructure, technological advancements, and robust research and development activities in the region.
Asia-Pacific is projected to be the fastest-growing region in the forecast period for gene therapy manufacturing due to clinical transformation and industrialization efforts. These initiatives contribute to the region's increasing prominence in the gene therapy market.
To know more about the study visit, https://www.databridgemarketresearch.com/pt/reports/global-viral-vector-and-vaccine-market
Recent Developments in Viral Vector and Vaccine Market
- In 2019, the FDA approved Zolgensma, a gene therapy using adeno-associated virus vectors, for treating spinal muscular atrophy (SMA) in infants under two. This therapy aims to address the underlying genetic cause of SMA by introducing a functional copy of the SMN1 gene to improve motor neuron function.
The Prominent Key Players Operating in the Viral Vector and Vaccine Market Include:
- Novasep (France)
- MerckKGaA (Germany)
- Charles River Laboratories (U.K.)
- uniQure N.V. (Netherlands)
- Waisman Biomanufacturing (U.S.)
- Creative-Biogene (U.S.)
- Aldevron (U.S.)
- Addgene (U.S.)
- Oxford Biomedica (U.K.)
- Thermo Fisher Scientific Inc (U.S.)
- Fujifilm Corporation (Japan)
- Spark Therapeutics Inc. (U.S.)
- ABL Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Brammer Bio (U.S.)
- Creative Biogene
- General Electric (U.S.)
- Pfizer Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of viral vector and vaccine market companies contact, https://www.databridgemarketresearch.com/pt/contact
Research Methodology: Global Viral Vector and Vaccine Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by dbmr research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
